eIF4E is the key regulator of protein translation and critical for translation. The oncogenic potential of tumorigenesis which is highly contingent on capdependent eIF4E also arises from the critical role in the nuclear export and cytosolic translation of oncogenic transcripts. Inhibition of Exportin1 (XPO1) which is the major nuclear export protein for eIF4Ebound oncoprotein mRNAs results in decreased tumor cell growth in vitro and vivo suggesting that eIF4E is critical in multiple myeloma (MM). Indeed we found that eIF4E is overexpressed in myeloma cell lines Since many transcription factors that are critical for MM proliferation exhibit a higher dependency on protein translation, eIF4E is an ideal and selective tool to target MM cell growth.
Abstract
eIF4E is the key regulator of protein translation and critical for translation. The oncogenic potential of tumorigenesis which is highly contingent on capdependent eIF4E also arises from the critical role in the nuclear export and cytosolic translation of oncogenic transcripts. Inhibition of Exportin1 (XPO1) which is the major nuclear export protein for eIF4Ebound oncoprotein mRNAs results in decreased tumor cell growth in vitro and vivo suggesting that eIF4E is critical in multiple myeloma (MM). Indeed we found that eIF4E is overexpressed in myeloma cell lines and primary myeloma cells compared to normal plasma cells. While stable overexpression of eIF4E in MM cells significantly increases tumorigenesis, knockdown of eIF4E impairs MM tumor progression in human xenograft mice model. Using a teton inducible eIF4Eknockdown system, eIF4Edownregulation, blocks MM tumor growth in vivo correlating with decreased eIF4E expression. Further overexpression and knockdown of eIF4E revealed that eIF4E regulates translation of mRNAs with highly complex 5'untranslated regions such as cMYC and C/EBPβ and subsequently proliferation in MM cells, but not in nonmalignant bone marrow stromal cells.
Since many transcription factors that are critical for MM proliferation exhibit a higher dependency on protein translation, eIF4E is an ideal and selective tool to target MM cell growth.
Introduction
eIF4E plays a central role in protein synthesis and has a key role in the control of cell growth, proliferation, differentiation, and metabolism in eukaryotic cells (1) . It recognizes and binds to the 7methylguanosine cap in the 5' untranslated regions (5'UTRs) of mRNAs, transporting these mRNAs to the eIF4F translation initiation complex, which includes eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A. An increase in eIF4E level or activity does not lead to increased rates of global translation, but instead results in increased translation of mRNAs with highly complex 5'untranslated regions (2) . Several genes including MYC, Cyclin D1, CCAAT/enhancerbinding protein beta (C/EBPβ) and vascular endothelial growth factor (VEGF) involved in tumorigenesis are regulated at the translational level by eIF4E (36) . Further eIF4E competitive inhibitors, such as XPO1 inhibitors, abrogate its prosurvival function by decreasing export and translation of target mRNAs (7) . In AML the XPO1 inhibitor KPT330 (Karyopharm Therapeutics) induced decreased levels of proteins derived from capped mRNAs associated with eIF4E mRNA, which are dependent upon XPO1 for nuclear export further suggesting a critical role for eIF4E (8) . Overexpression and/or activation of eIF4E has been also associated with tumor formation and progression including lymphoma, and cancers of the breast, colon, lung and prostate (9) , but the role of eIF4E in multiple myeloma is largely unknown.
Multiple myeloma (MM) is a plasma cell disorder, associated with an accumulation of monoclonal terminally differentiated plasma cells within the bone marrow, and usually the presence of a monoclonal immunoglobulin (10) . In 2012, approximately 21,700 new cases were diagnosed in the US and estimated 10,710 deaths occurred from this disease (11) . Even with the introduction of novel and more potent treatment regimens for MM, the disease remains an incurable plasma cell malignancy (12) velcade showed synergistic anti MM effect (13) . 4EGI1 behaves as a functional 4EBP1 mimetic inhibiting the interaction between eIF4E and eIF4G and decreases the expression of eIF4E regulated proteins in myeloma cells (14) . More recently AttarSchneider at al investigated by high throughput assay of mRNA microarrays the significance of eIF4E/eIF4GI silencing to transcription factors, microRNAs and phenotype. They showed that different imprints for eIF4E and eIF4GI affect the expression of cellular proteome, transcription factors, microRNAs, and phenotype in MM (15) .
Taken together, since tumor cell growth is more contingent on capdependent protein translation than normal tissues(16) the role of eIF4E in tumorigenesis and cancer progression has generated increasing interest as a therapeutic target in cancer (13, 1621) . Frequent mutations in genes involved in mRNA translation resulting in increased protein translation support the role of translational control in the pathogenesis of multiple myeloma (22) . Here we provide novel insights into the role of the translation initiation factor eIF4E in MM tumor growth. By overexpressing and knockdown of eIF4E as well as using an inducible eIF4EshRNA in human MM xenograft mouse models we found that expression of critical transcription factors and subsequently MM tumor growth is highly dependent on eIF4E expression. Therefore direct or functional inhibition of eIF4E by competitive selective inhibitors of nuclear export (XPO1 inhibitors) such as KPT330, abrogate its prosurvival function by decreasing export and translation of target mRNAs and represent a promising approach.
Materials and Methods

Chemicals and antibodies
Cell culture media, sera and penicillinstreptomycin were purchased from Gibco BRL months. The MM cell lines MM.1S, RPMI8226, U266, H929 and OPM2 were cultured in RPMI 1640 plus 10% FBS and 100 U/mL penicillin/streptomycin at 37°C and 5% CO 2 as described before (23) . Human MM cells were isolated from patient bone marrow samples as described before (24) . Mononuclear cells were isolated by Ficoll (Invitrogen, Carlsbad, CA) followed by magnetic separation using CD138 + antibodyspecific micro beads according to the manufacturer's protocol (Miltenyi Biotech, Auburn, CA). For the determination of mRNA levels of eIF4E and cMYC, total RNAs were isolated from cells using Trizol reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. Total RNA was converted into cDNA using Superscript III RT (Invitrogen). Quantitative RTPCR was performed as described before (23) . The following primer sets were used: 
Transduction of pCDH-GFP and pCDH-GFP-eIF4E
Expression vectors for the fulllength wildtype eIF4E were generated by inserting the respective coding regions into pCDHGFP vector. In brief, fulllength human eIF4E cDNA was cut out from pHAeIF4E (Addgene, Cambridge, MA) (27) by HindIII/XhoI double digestion ACTCTGTAATAGTTCAGTA3'. The shRNA stable transfectants were obtained by puromycin (5 μg/ml) selection and analyzed by western blotting or cell proliferation assay. For teton inducible eIF4E knockdown MM cells, tetonpLKOpuro (Addgene, Cambridge, MA)(28) was used to generate inducible sheIF4E lentiviral construct with the same target sequence as above and the correct constructs were confirmed by DNA sequencing. The viruses containing empty vector sequences were used as a control. RPMI8266 or U266 cells were incubated with lentivirus particle and polybrene 8 µg/ml for 16h, and then washed with media. Transduced MM cells were maintained in 10% tetracyclinefree FBS(Clontech, Mountain View, CA). Cells were selected for 3 days in puromycin (5µg/ml). The efficiency of virus transduction was determined by puromycinresistance and the transduction rate of U266 or RPMI8266 was greater than 60% or 70%, respectively. Selected cells were treated with or without doxycycline (200 ng/ml) for 3 days to induce knockdown eIF4E.
Cell Cycle assays
MM Cells (1×10 6 cells/ml) were cultured for 72 hours at 37°C, harvested, and washed with ice cold PBS, fixed with 70% ethanol for 1 h at 4°C, and pretreated with RNase (Worthington, Lakewood, NJ) for 30 min at 37°C. Cells were stained with PI (20µg/mL) (Sigma Aldrich). ) in 100 µL PBS together with an equal volume of Matrigel basement membrane matrix (BD Biosciences) were injected subcutaneously (s.c.). Mice were weighed twice weekly and observed daily for diarrhea or any changes in behavior and condition. Tumor sizes were measured twice weekly in a no blinded manner. After mice were sacrificed, the tumors were excised, weighed and taken pictures. Tumor weights are reported as mean ± SEM (n = 5). CT teton shRNA or eIF4Eteton shRNA cells were injected subcutaneously into SCID/bg mice. 11 days after implantation, animals were randomized to receive either vehicle (5% sucrose) or doxycycline (1mg/ml in 5% sucrose) via drinking water for duration of study. 
Statistical analyses
Each experiment was repeated at least 3 times, and all quantitative data are presented as mean ± SEM. Statistical differences were determined by Student's ttest (two tailed). The results were considered statistically significant if P <0.05.
Results
eIF4E is highly expressed in primary myeloma cells and myeloma cell lines
We examined eIF4E expression in normal plasma cells, primary 
not the CTshRNA led to significant reduction of eIF4E expression at protein (Figure 2A ) and mRNA ( Figure 2B ) levels. Silencing of eIF4E in myeloma cells significantly inhibited cell growth (66% in RPMI8226, 76% in U266, P<0.01)( Figure 2C ). In accordance with that, cell cycle analysis revealed that knockdown of eIF4E decreased the cell numbers in Sphase with concomitant increase of cells in G0/G1 growth arrest (63% vs 75% in U266 cells) (37% vs 50% in RPMI8226) ( Figure 2D ). Importantly, eIF4E knockdown resulted in significant reduction Figure 2E ). Next we established an inducible eIF4E knockdown in our MM cells. We stably infected U266 and RPMI8226 with shRNA lentivirus generated from a robust inducible knockdown vector pLKOtetOn. Doxycyclineinduced eIF4EtetonshRNA expression resulted in significant decrease of eIF4E protein ( Figure 2F ) and significantly inhibited (RPMI by 72% and U266 by 46%, P<0.01) cell growth ( Figure 2G ). To determine whether eIF4E is specifically critical for MM cells growth, we tested its role in primary stromal cells from MM patients, which exhibit a low eIF4E expression (Supplementary Figure 1) .
Primary stromal cells were similarly infected with eIF4EshRNA or CTshRNA lentivirus and stably transfected cells were obtained after puromycin selection ( Figure 2H ). Interestingly, silencing of eIF4E in stromal cells did not affect proliferation ( Figure 2I ), indicating that eIF4E is specifically critical for malignant cells growth in MM cells.
Ectopic overexpression of eIF4E significantly increases multiple myeloma cell growth in vitro
To examine the effects of overexpression of eIF4E on MM, we transduced RPMI8226 and U266 cells with lentiviral particles encoding human eIF4E with GFP as selection marker. eIF4E overexpression (OE) was confirmed by western blotting and RTPCR ( Figure 3A, B) . Overexpression of eIF4E resulted in significant (p<0.001) increase of MM cell growth compared to EV control cells ( Figure 3C ). Cell cycle analysis revealed decreased population of U266 cells in G0/G1 (62% vs 49%) and RPMI8226 cells in G0/G1 (40% vs 31%) ( Figure 3D ), and without significant effects on cell apoptosis in U266 (Supplementary Figure 2) . Overexpression of eIF4E further led to the significant increase (p=0.004) of clonogenic MM tumor growth with expansion of clonogenic colony numbers (22.3 ± 2.5 vs 40.3 ± 2.1 in U266) and (23± 1 vs 39.3 ± 5.7 in RPMI8226)( Figure 3E ).
eIF4E is critical for multiple myeloma tumorigenesis in vivo
To determine the role of high expression of eIF4E in MM tumor growth in vivo, we generated subcutaneous MM xenografts in severe combined immunodeficient x beige (SCID/bg) mice using the U266CTshRNA and U266eIF4EshRNA cells. Mice injected with U266eIF4E shRNA cells showed a significant (P<0.001) and up to 90% decreased tumor size after 23 days ( Figure 4A ). To determine whether overexpressed eIF4E induces MM tumor growth in vivo, we injected EVU266 or eIF4EOEU266 cells subcutaneously. In contrast to EVU266 tumors, animals bearing eIF4EOEU266 xenografts showed a significant increase (p<0.001) of tumor growth (180%) after 13 days ( Figure 4B ). Next we wanted to explore whether the further growth of already established tumors depends on eIF4E by using a teton inducible knockdown system. We generated subcutaneous MM xenografts in SCID/bg mice using the inducible U266tetCT Prior and current studies of the effects of eIF4E on proteins regulating cell growth and cell cycle revealed that cMYC, IRF4 and C/EBPβ protein expression level correlates with eIF4E expressions in MM cells (23, 32) . In contrast, normal plasma and CD138 cells showed very low or no detectable expression levels of eIF4E as well as cMYC, IRF4 and C/EBPβ. Knockdown and introduction of ectopic eIF4E resulted in down and up regulation of MYC, IRF4 and C/EBPβ suggesting that those factors depend on eIF4Emediated protein translation ( Figure 5A ). In 
multiple myeloma, MYC, IRF4 and C/EBPβ are essential for malignant tumor growth. cMYC is activated in multiple myeloma cells (30, 34) and targeting MYC by short hairpin RNA induces cell death in myeloma cell lines (31) . Further MYC overexpression in tumorigenesis is linked to increased eIF4E activity and upregulated protein synthesis (33, 37) . IRF4 was identified as an oncogene associated with the chromosomal translocation t(6;14) (p25;q32)(38) controlling MM survival(31) and overexpression of IRF4 is an adverse prognostic survival marker (31, 39) . IRF4 is a target of lenalidomide in MM (23, 40) . Interestingly, in myeloma, IRF4 and cMYC mutually reinforce the expression of each other (31) . Taken together, these data suggest that high expression or at least a critical threshold of eIF4E is required for protein translation of subcutaneously into SCID/bg mice. 11 days after implantation, animals were randomized to receive either vehicle (5% sucrose) or doxycycline (1mg/ml in 5% sucrose) via drinking water for duration of study. Mice were sacrificed after 22 day. (D) Tumors harvested at the end of the study were fixed in formalin and subsequently processed for immunohistochemical staining for eIF4E. Images (×630 magnification) were acquired using Leica DMI 6000B microscope. 
